Forbion Capital Partners (Forbion) is a leading venture capital firm that works closely with entrepreneurs to build life sciences companies with technologies and products designed to transform people’s lives.
Forbion currently manages over €700m across six closed-end funds, including its $200m+ FCFIII fund, launched in 2016, actively looking for new exciting opportunities. Forbion has a team of ten investment professionals across two offices, in Naarden (NL) and Munich (DE) plus representation in Boston (USA). Forbion’s underlying portfolio theme is private companies developing novel drugs, medical devices and diagnostics for high, or even unmet, medical needs. Forbion helps companies to bridge research and development, not just financially via its six funds, but also through the team’s expertise in development and company building. The current portfolio comprises around 27 active investments in companies working on a range of globally important disease areas of high unmet medical need. Portfolio companies are typically working in the fields of cancer, kidney disease, liver disease, dyslipidemia, inflammatory bowel disease, anti-infectives, central nervous system pain management, and the micro biome. Recent examples include Dezima sold to Amgen for up to $1.55bn and the sale of Acerta Pharma to Astra Zeneca for a total exit value of $7bn (investment by Forbion’s affiliate BioGeneration Ventures).